# Final Report: Idea 74

## Final ELO Score: 1211.8

## Final Hypothesis

**Title**: Bispecific IgG-Fc/Endolysin Fusion that Simultaneously Opsonises and Lyses Pneumococci

**Key Idea**: A human Fc fused to CHAP lysin and an extra scFv against pneumococcal PspA enhances half-life, immune recruitment, and specificity, effecting rapid clearance of drug-resistant strains.

**Paragraph**: Fc fusion improved PK; adding a PspA-binding scFv heightens localisation at infection sites and broadens capsule-independent killing.

**Approach**: CHO expression; ADCC & complement activation assays; rat PK; invasive pneumonia efficacy vs. penicillin-R clones.

**Key References**: Fischetti 2010; Schuch 2020; Roopenian 2007; NEW—Sokullu et al., Adv. Sci., 2022 (bispecific Fc fusions) [Sokullu 2022].  
Modifications: Added scFv specificity module and complement assays; bolsters targeting.

────────────────────────────────────────────────────────
IDEA 39  
────────────────────────────────────────────────────────

## Comprehensive Analysis

This document provides a full analysis of the idea, including its evolution, strengths, weaknesses, and potential applications. Below we trace the development of this idea through each phase of the research process.

## Evolution History

The idea underwent several iterations during the research process:

## Detailed Breakdown

### Title

Bispecific IgG-Fc/Endolysin Fusion that Simultaneously Opsonises and Lyses Pneumococci

### Key Idea

A human Fc fused to CHAP lysin and an extra scFv against pneumococcal PspA enhances half-life, immune recruitment, and specificity, effecting rapid clearance of drug-resistant strains.

### Detailed Explanation

Fc fusion improved PK; adding a PspA-binding scFv heightens localisation at infection sites and broadens capsule-independent killing.

### Implementation Approach

CHO expression; ADCC & complement activation assays; rat PK; invasive pneumonia efficacy vs. penicillin-R clones.

### Key References

Fischetti 2010; Schuch 2020; Roopenian 2007; NEW—Sokullu et al., Adv. Sci., 2022 (bispecific Fc fusions) [Sokullu 2022].  
Modifications: Added scFv specificity module and complement assays; bolsters targeting.

────────────────────────────────────────────────────────
IDEA 39  
────────────────────────────────────────────────────────

## Complete Evolution History

This section documents the complete evolution of the idea through each phase of the research process.

### 1. Evolution (Round 4)
**Timestamp:** 2025-05-07 10:43:26



### 2. Reflection (Round 4)
**Timestamp:** 2025-05-07 10:44:53



### 3. Proximity Check (Round 4)
**Timestamp:** 2025-05-07 10:45:31



### 4. Ranking (Round 4)
**Timestamp:** 2025-05-07 10:45:39



### 5. Round Summary (Round 4)
**Timestamp:** 2025-05-07 10:46:18



### 6. Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1211.8



### 7. Final Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1211.8



## Citations

- Sokullu 2022
